Is biocept Inc (BIOC) a good stock to buy?
Apr 08, 2022 · Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor...
Where can I buy BIOC shares?
Apr 02, 2022 · Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.
What is the Bioc stock price prediction for 2026-12-16?
Apr 13, 2022 · Real-time trade and investing ideas on Biocept BIOC from the largest community of traders and investors.
How often does walletinvestor predict the price of BIOC?
Biocept, Inc. Common Stock (BIOC) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Is Bioc a good stock to buy?
Is BIOCEPT Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: BIOC) stock is to Strong Buy BIOC stock.
Why did Bioc stock drop?
Shares of Biocept Inc. BIOC, -4.29% plummeted 42% on very heavy volume in morning trading Monday, after the provider of liquid cancer tests announced the pricing of stock offering at a deep discount.Mar 2, 2020
Is Biocept a buy right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2...
How has Biocept's stock been impacted by Coronavirus (COVID-19)?
Biocept's stock was trading at $3.7690 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organi...
When is Biocept's next earnings date?
Biocept is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022. View our earnings forecast for Biocept .
How were Biocept's earnings last quarter?
Biocept, Inc. (NASDAQ:BIOC) released its earnings results on Monday, November, 15th. The medical research company reported $0.03 EPS for the quarte...
When did Biocept's stock split? How did Biocept's stock split work?
Shares of Biocept reverse split on the morning of Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020....
Who are Biocept's key executives?
Biocept's management team includes the following people: Michael W. Nall , President, Chief Executive Officer & Director Timothy C. Kennedy , CF...
What is Michael Nall's approval rating as Biocept's CEO?
1 employees have rated Biocept CEO Michael Nall on Glassdoor.com . Michael Nall has an approval rating of 100% among Biocept's employees. This put...
Who are some of Biocept's key competitors?
Some companies that are related to Biocept include Celcuity (CELC) , Sera Prognostics (SERA) , Exagen (XGN) , MDxHealth (MDXH) , Centogene (CN...
What other stocks do shareholders of Biocept own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO) , iBio...
Recently Viewed Tickers
Biocept Inc
Visit a quote page and your recently viewed tickers will be displayed here.
Is Biocept a buy right now?
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.
What stocks does MarketBeat like better than Biocept?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.#N#View analyst ratings for Biocept or view top-rated stocks.
When is Biocept's next earnings date?
Wall Street analysts have given Biocept a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biocept wasn't one of them.
How were Biocept's earnings last quarter?
Biocept is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.#N#View our earnings forecast for Biocept.
How has Biocept's stock been impacted by COVID-19 (Coronavirus)?
Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Sunday, August, 15th. The medical research company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.02.
When did Biocept's stock split? How did Biocept's stock split work?
Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIOC stock has decreased by 0.2% and is now trading at $3.76.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for BIOC?
Biocept's stock reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020.
Signals & Forecast
1 equities research analysts have issued 12-month price targets for Biocept's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biocept's share price to reach $20.00 in the next year.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Tuesday, August 24, 2021, and so far it has risen 11.80%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD).
Is Biocept stock A Buy?
Biocept finds support from accumulated volume at $3.69 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Biocept, Inc. (BIOC)
Biocept holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Zacks' 7 Best Strong Buys for September, 2021
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Thematic ETF Investing: What You Should Know
Zacks has a proven record of recommending stocks with major upside potential. This report reveals 7 stocks predicted to have explosive gains over the next 30-90 days. A recent pick, Fiverr, spiked +84.6% in just 30 days. In today's bull market, these stocks could climb even higher. See our 7 Best Stocks absolutely FREE.
Bull of the Day
In this episode of ETF Spotlight, Zacks Chief ETF Strategist Neena Mishra speaks with Jay Jacobs, Head of Research & Strategy at Global X, about thematic investing.
ETFs
Earnings momentum looks to take this stock to all-time highs and beyond.
Mutual Funds
Here we highlight a few ETFs that can gain from the strength in the tech-heavy Nasdaq Composite.
Options
Below, we share with you three top-ranked mid-cap growth mutual funds. Each has earned a Zacks Mutual Fund Rank #1...
